Skip to content

Apogee Therapeutics, Inc.

APGE

CIK 0001974640

← back to feed
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
−$260.57M
−40.5% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$4.25
−27.9% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
−$151.39M
Q1 Mar 2026
Cash
$451.8M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
74.88M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings